Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-10-10)Premium Content

Novartis Ag (NVS)

2014-10-22@16:30:09 ET
Innocoll AG Proposes Changes to Supervisory Board and Stock Option Plan (PMZ)

2014-10-22@16:09:58 ET
Potential Novartis AG (NVS) Trade Targets 2.21% Return (FBM)

2014-10-22@08:38:06 ET
US Patent Issued to Novartis on Oct. 21 for "Heterocyclic derivatives and their use in the treatment of neurological disorders" (German, Swiss, Indian, French Inventors) (ABW)

2014-10-22@06:55:18 ET
Anti-Inflammatory Peptides Competitor Analysis Report 2014 (MTO)

2014-10-22@06:39:28 ET
US Patent Issued to Novartis on Oct. 21 for "Heterocyclic compounds and uses thereof" (California, Massachusetts Inventors) (ABW)

2014-10-21@20:21:29 ET
European ETFs Plunge As Trouble Hits Region's Core (ABW)

2014-10-21@12:38:45 ET
Novartis AG (NVS) Showing Bearish Technicals With Resistance At $88.96 (FBM)

2014-10-21@10:01:32 ET
Rabies Virus Vaccines, Antibodies and Immune Globulins Competitor Analysis (MTO)

2014-10-21@08:30:04 ET
Fidelity Biosciences and Atlas Venture Lead $12 Million Series A Funding to Launch Unum Therapeutics, a New Cellular Immunotherapy Company (BIZ)

2014-10-21@08:20:06 ET
Viamet secures USD60m in Series D round (MTN)

2014-10-21@07:00:34 ET
Viamet Announces $60 Million Series D Financing (BIZ)

2014-10-21@07:00:00 ET
Novartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song(TM) (PRN)

2014-10-21@04:50:52 ET
Monoclonal Antibody Industry 2014-2019 Global and China A New Research Report at ChinaMarketResearchReports.com (PRW)

2014-10-21@04:09:06 ET
Competitor Analysis: Ebola Virus Vaccines and Therapeutics Report 2014 Featuring Over 30 Insitutions (MTO)

2014-10-21@01:52:02 ET
Despite Generic Releases Report on Renal Cell Carcinoma Market (CLM)

2014-10-20@18:11:19 ET
Watch for Novartis to Potentially Pullback After Gaining 1.47% Yesterday (PSM)

2014-10-20@18:10:48 ET
Novartis Set to Possibly Pullback After Yesterday's Rally of 1.47% (PSM)

2014-10-20@15:10:00 ET
Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis (PRN)

2014-10-20@15:01:42 ET
Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis (HUG)

2014-10-20@14:00:00 ET
The Age-Related Macular Degeneration Drug Market Will Grow to Nearly $9 Billion in 2023, Fueled in Part by the Anticipated Launch of the First Therapies for Geographic Atrophy (PRN)